| 產品編號 | bsm-61004R |
| 英文名稱 | UPK3A Recombinant Rabbit mAb |
| 中文名稱 | 尿路上皮特異蛋白3重組兔單抗 |
| 別 名 | Uroplakin III; MGC119178; OTTHUMP00000028951; UP III; UP3A; UPIII; UPIIIA; UPK 3; UPK 3A; UPK3; UPK3A_HUMAN; Uroplakin 3A; Uroplakin III; Uroplakin-3a; Uroplakin3A; UroplakinIII. |
| 抗體來源 | Rabbit |
| 克隆類型 | Recombinant |
| 克 隆 號 | 19A15 |
| 交叉反應 | Human,Mouse |
| 產品應用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 29 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human UPK3A |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
The asymmetric unit membrane (AUM) forms numerous plaques, which cover the apical surface of the urothelium. These plaques are thought to strengthen the urothelium and reduce the risk of rupturing during ladder distention. They are composed of four major integral membrane proteins called uroplakins (UP). The uroplakin family comprises UPIa, UPIb, UPII, and UPIII. Family members are conserved among several species, including human, mouse, rat, rabbit, dog, pig and sheep. UPIa and UPIb form tightly packed structures with UPII and UPIII, respectively. This pairing is required for normal urothelial plaque formation and is regulated by proteolytic processing of the uroplakin proteins. Uroplakins are expressed in normal urothelium and are used as specific markers of urothelial differentiation. They are also expressed in a majority of transitional cell carcinomas of the bladder (TCCs), which make the uroplakins a useful marker for detecting bladder cancer metastasis and for staging and monitoring chemotherapeutic response. Function: Component of the asymmetric unit membrane (AUM); a highly specialized biomembrane elaborated by terminally differentiated urothelial cells. May play an important role in AUM-cytoskeleton interaction in terminally differentiated urothelial cells. It also contributes to the formation of urothelial glycocalyx which may play an important role in preventing bacterial adherence. Subcellular Location: Endoplasmic reticulum membrane. Heterodimer formation with UPK1B is a prerequisite to exit out of the endoplasmic reticulum (ER). Tissue Specificity: Expressed in ureter. DISEASE: Defects in UPK3A are a cause of renal adysplasia (RADYS) [MIM:191830]; also known as renal agenesis or renal aplasia. Renal agenesis refers to the absence of one (unilateral) or both (bilateral) kidneys at birth. Bilateral renal agenesis belongs to a group of perinatally lethal renal diseases, including severe bilateral renal dysplasia, unilateral renal agenesis with contralateral dysplasia and severe obstructive uropathy. Similarity: Belongs to the uroplakin-3 family. Database links: Entrez Gene: 7380 Human Omim: 611559 Human SwissProt: O75631 Human SwissProt: Q32N05 Human Unigene: 632787 Human |
| 產品圖片 |
Paraformaldehyde-fixed, paraffin embedded Human Bladder; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with UPK3A Monoclonal Antibody, Unconjugated(bsm-61004R) at 1:400 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Mouse Bladder; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with UPK3A Monoclonal Antibody, Unconjugated(bsm-61004R) at 1:500 overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023) and DAB (C-0010) staining.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
